Beyond Mutational Profiling: Enhancing Cancer Biomarker Strategies with RNA
|SPEAKER:||Sean Ferree, PhD, Vice President of Product Development, NanoString|
Nov 28, 2018 - Nov 28, 2018
Cancer is highly heterogenous on a molecular and cellular level, leading to heterogenous clinical outcomes. It has been known for decades that cancer is a genetic disease, but researchers have also known than DNA is not the whole answer. Recently, the value of including gene expression measurements in cancer case management has moved to the forefront of cancer research. This webinar reviews some of the recent studies where RNA signatures enhanced study outcomes. Dr. Ferree will also introduce Nanostring® cancer-focused products and services and address how they can accelerate RNA signature discovery and translation.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.